{"transactions":[{"id":1147,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-02T21:48:11.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":9682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026."}],"balance_after":11363,"source":{"system":"sec-edgar","filing":"0001329154-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1615219/000132915426000003/ownership.xml","form_type":"4"}},{"id":992351,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2025-11-20T16:42:09.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.8,"value":16000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20 shares of unvested restricted stock granted on January 3, 2023."}],"balance_after":20177,"source":{"system":"sec-edgar","filing":"0001615219-25-000177","document":"wk-form4_1763674926.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521925000177/wk-form4_1763674926.xml","form_type":"4"}},{"id":1624979,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-22T16:37:10.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options are vested on  February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months."}],"balance_after":22500,"derivative":{"exercise_price":0.5711,"exercise_date":"2025-02-20","expiration_date":"2034-02-19","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001615219-24-000015","document":"wk-form4_1708637819.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521924000015/wk-form4_1708637819.xml","form_type":"4"}},{"id":2013284,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2023-02-15T16:06:23.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":6432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement"}],"balance_after":21851,"source":{"system":"sec-edgar","filing":"0001615219-23-000025","document":"wf-form4_167649515529108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521923000025/wf-form4_167649515529108.xml","form_type":"4"}},{"id":2061955,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2023-01-05T17:35:53.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter."}],"balance_after":15419,"source":{"system":"sec-edgar","filing":"0001615219-23-000004","document":"wf-form4_167295812977872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521923000004/wf-form4_167295812977872.xml","form_type":"4"}},{"id":2089421,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-12-12T18:29:33.000Z","date":"2022-11-03","kind":"grant","acquired":true,"shares":1488,"price":1.734,"value":2580.192,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 7,314 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 1,488 shares of common stock."}],"balance_after":7419,"source":{"system":"sec-edgar","filing":"0001615219-22-000153","document":"wf-form4a_167088775808803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000153/wf-form4a_167088775808803.xml","form_type":"4/A","original_submission_date":"2022-11-07"}},{"id":2122093,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-11-08T17:40:57.000Z","date":"2022-11-03","kind":"grant","acquired":true,"shares":7314,"price":1.734,"value":12682.476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c)"}],"balance_after":13245,"source":{"system":"sec-edgar","filing":"0001615219-22-000143","document":"wf-form4a_166794723949586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000143/wf-form4a_166794723949586.xml","form_type":"4/A","original_submission_date":"2022-11-07"}},{"id":2123316,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-11-07T16:33:50.000Z","date":"2022-11-03","kind":"grant","acquired":true,"shares":7314,"price":1.734,"value":12682.476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c)."}],"balance_after":155633,"source":{"system":"sec-edgar","filing":"0001615219-22-000141","document":"wf-form4_166785680873414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000141/wf-form4_166785680873414.xml","form_type":"4"}},{"id":2251011,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-05-31T17:13:28.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":28000,"price":0.18,"value":5040.0,"ownership":{"direct":true},"balance_after":148319,"source":{"system":"sec-edgar","filing":"0001615219-22-000085","document":"wf-form4_165403159108429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000085/wf-form4_165403159108429.xml","form_type":"4"}},{"id":2280601,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-05-05T16:03:28.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":10000,"price":0.1863,"value":1863.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares  and receive these shares in lieu of net cash compensation. Shares are  purchased at a  price determined pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":120319,"source":{"system":"sec-edgar","filing":"0001615219-22-000067","document":"wf-form4_165178098962212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000067/wf-form4_165178098962212.xml","form_type":"4"}},{"id":2341358,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2022-03-09T16:03:00.000Z","date":"2022-03-03","kind":"purchase","acquired":true,"shares":76246,"price":0.391,"value":29812.186,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant."}],"balance_after":110319,"source":{"system":"sec-edgar","filing":"0001615219-22-000019","document":"wf-form4_164685975971462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000019/wf-form4_164685975971462.xml","form_type":"4"}},{"id":2428632,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-21T16:03:37.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options are fully vested on January 19, 2023, and 1/36 of the remaining options vest on each monthly anniversary thereafter."}],"balance_after":200000,"derivative":{"exercise_price":0.48,"expiration_date":"2032-01-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001615219-22-000004","document":"wf-form4_164279899941926.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521922000004/wf-form4_164279899941926.xml","form_type":"4"}},{"id":2522669,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2021-11-05T14:54:02.000Z","date":"2021-11-03","kind":"grant","acquired":true,"shares":7787,"price":0.718,"value":5591.066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":34073,"source":{"system":"sec-edgar","filing":"0001615219-21-000095","document":"wf-form4_163613842601112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521921000095/wf-form4_163613842601112.xml","form_type":"4"}},{"id":2726775,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2021-05-05T17:11:53.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":9563,"price":0.567,"value":5422.221,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":26286,"source":{"system":"sec-edgar","filing":"0001615219-21-000042","document":"wf-form4_162024909680344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521921000042/wf-form4_162024909680344.xml","form_type":"4"}},{"id":2956350,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-04T17:02:09.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options are fully vested on December 1, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter."}],"balance_after":80000,"derivative":{"exercise_price":0.74,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001615219-20-000120","document":"wf-form4_160711931578964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000120/wf-form4_160711931578964.xml","form_type":"4"}},{"id":2990881,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2020-11-05T17:42:14.000Z","date":"2020-11-03","kind":"grant","acquired":true,"shares":4723,"price":0.561,"value":2649.603,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares  and receive these shares in lieu of net cash compensation. Shares are  purchased at a  price determined pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":16723,"source":{"system":"sec-edgar","filing":"0001615219-20-000104","document":"wf-form4_160461612138517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000104/wf-form4_160461612138517.xml","form_type":"4"}},{"id":3053672,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2020-08-18T08:35:16.000Z","date":"2020-08-17","kind":"purchase","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001615219-20-000092","document":"wf-form4_159775410165354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000092/wf-form4_159775410165354.xml","form_type":"4"}},{"id":3081507,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-16T20:55:39.000Z","date":"2020-07-14","kind":"grant","acquired":true,"shares":49955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options are fully vested on July 14, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter."}],"balance_after":49955,"derivative":{"exercise_price":1.32,"expiration_date":"2030-07-13","underlying":"Common Stock","underlying_shares":49955},"source":{"system":"sec-edgar","filing":"0001615219-20-000080","document":"wf-form4_159494732561482.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000080/wf-form4_159494732561482.xml","form_type":"4"}},{"id":3195081,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2020-03-25T18:03:05.000Z","date":"2020-03-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options granted are fully vested on March 23, 2021, and quarterly vesting of the remaining options over 3 years"}],"balance_after":30000,"derivative":{"exercise_price":0.61,"expiration_date":"2030-03-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001615219-20-000027","document":"wf-form4_158517376702567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000027/wf-form4_158517376702567.xml","form_type":"4"}},{"id":3259022,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2020-02-20T16:07:57.000Z","date":"2020-02-19","kind":"purchase","acquired":true,"shares":2000,"price":0.95,"value":1900.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001615219-20-000005","document":"wf-form4_158223286008604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000005/wf-form4_158223286008604.xml","form_type":"4"}},{"id":3273531,"issuer":{"id":937,"kind":"organization","name":"Decoy Therapeutics Inc.","symbol":"DCOY"},"owners":[{"id":969,"kind":"person","name":"Rosenblum Mark J","position":1,"cik":"0001329154","reported_name":"Rosenblum Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec VP Finance, CFO"}}],"security":"Common Stock","published_at":"2020-02-13T17:57:33.000Z","date":"2020-02-13","kind":"purchase","acquired":true,"shares":5000,"price":0.859,"value":4295.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001615219-20-000001","document":"wf-form4_158163463653747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329154/000161521920000001/wf-form4_158163463653747.xml","form_type":"4"}}]}